EFFICACY AND SAFETY OF ZOFENOPRIL+HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN+HYDROCHLOROTHIAZIDE COMBINATION IN METABOLIC SYNDROME PATIENTS WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS MONOTHERAPY

Trial Profile

EFFICACY AND SAFETY OF ZOFENOPRIL+HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN+HYDROCHLOROTHIAZIDE COMBINATION IN METABOLIC SYNDROME PATIENTS WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS MONOTHERAPY

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Zofenopril (Primary) ; Hydrochlorothiazide; Irbesartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ZAMES
  • Sponsors Menarini
  • Most Recent Events

    • 17 Jun 2013 Results presented at the 23rd European Meeting on Hypertension.
    • 06 Apr 2013 Primary endpoint 'Office-blood-pressure' has been met.
    • 06 Apr 2013 Primary endpoint 'Diastolic-blood-pressure' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top